Michael Ulz

Q: How accurate are Michael Ulz's stock ratings?

About 45% of Michael's ratings were profitable over a one-year hold, with an average return of -3.4% per rating, measured by 13Foresight from historical prices.

Q: How is Michael ranked?

Michael Ulz is ranked #1947 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Morgan Stanley

Wall Street Analyst

★★★☆☆

#1947

on 13Foresight · ranked by our own returns

45%

Success Rate

-3.4%

Average Return

44 of 98 calls profitable · -123.6% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 45% of Michael Ulz's ratings turned a profit when each position was held for 1 year — averaging -3.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

104 Buy 64 Hold 4 Sell

Michael's Stock Coverage 43 ratings · 2026-09-10

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
DYN Dyne Therapeutics	Sep 09, 2026	BUY	Strong Buy +104.4% avg upside 31 analysts	$36.00 87.58% Upside	·	·
IONS Ionis Pharmaceuticals	Sep 09, 2026	BUY	Strong Buy +38.3% avg upside 43 analysts	$104.00 85.62% Upside	·	·
GUTS Fractyl Health, Inc.	Sep 01, 2026	HOLD	Strong Buy +614.0% avg upside 7 analysts	$2.00 212.57% Upside	-1.6%	·
ARWR Arrowhead Pharmaceuticals	Aug 31, 2026	BUY	Strong Buy -9.8% avg upside 28 analysts	$120.00 45.13% Upside	+4.8%	·
RYTM Rhythm Pharmaceuticals	Aug 24, 2026	BUY	Strong Buy +23.2% avg upside 21 analysts	$150.00 48.34% Upside	-9.2%	·
CABA Cabaletta Bio	Aug 17, 2026	BUY	Strong Buy +391.3% avg upside 16 analysts	$13.00 346.78% Upside	+20.1%	·
RCKT Rocket Pharmaceuticals	Aug 12, 2026	HOLD	Buy +357.9% avg upside 30 analysts	$5.00 37.66% Upside	+13.2%	·
AARD Aardvark Therapeutics, Inc.	Aug 12, 2026	SELL	Buy +300.5% avg upside 12 analysts	$3.00 39.08% Downside	+18.1%	·
KYTX Kyverna Therapeutics, Inc.	Aug 12, 2026	BUY	Strong Buy +261.6% avg upside 7 analysts	$33.00 332.00% Upside	+2.5%	·
SLN Silence Therapeutics	Aug 11, 2026	BUY	Strong Buy +161.3% avg upside 10 analysts	$32.00 136.20% Upside	-0.9%	·
BIOA BioAge Labs, Inc.	Aug 07, 2026	HOLD	Strong Buy +296.7% avg upside 9 analysts	$20.00 118.12% Upside	-21.8%	·
ZNTL Zentalis Pharmaceuticals	Aug 07, 2026	HOLD	Buy +275.3% avg upside 18 analysts	$5.00 31.51% Upside	-5.5%	·
MIRM Mirum Pharmaceuticals	Aug 06, 2026	BUY	Strong Buy +15.2% avg upside 22 analysts	$137.00 39.34% Upside	+4.5%	·
VIR Vir Biotechnology	Aug 06, 2026	BUY	Strong Buy +138.3% avg upside 16 analysts	$25.00 131.28% Upside	+29.9%	·
SRPT Sarepta Therapeutics	Aug 06, 2026	HOLD	Buy +175.1% avg upside 49 analysts	$25.00 13.60% Upside	+34.1%	·
ALNY Alnylam Pharma	Jul 31, 2026	HOLD	Strong Buy +27.3% avg upside 51 analysts	$300.00 16.24% Upside	+20.4%	·
VKTX Viking Therapeutics	Jul 30, 2026	BUY	Strong Buy +120.5% avg upside 31 analysts	$95.00 190.60% Upside	+1.7%	·
TNYA Tenaya Therapeutics	Jun 03, 2026	BUY	Strong Buy +1426.9% avg upside 11 analysts	$2.00 202.66% Upside	-15.9%	·
IOBTQ IO Biotech	Jan 08, 2026	SELL	Hold +471499900.1% avg upside 6 analysts	$0.36 35999900.08% Upside	·	·
XLO Xilio Therapeutics	Mar 11, 2025	BUY	Strong Buy +91.9% avg upside 7 analysts	$5.00 44.32% Downside	-31.9%	·
FATE Fate Therapeutics	Mar 06, 2025	HOLD	Buy +410.6% avg upside 31 analysts	$5.00 104.85% Upside	+27.9%	·
HLIT Harmonic	Feb 11, 2025	HOLD	Buy +12.5% avg upside 14 analysts	$5.00 57.59% Downside	+6.3%	·
KLRS Kalaris Therapeutics	Aug 13, 2024	SELL	Buy +266.3% avg upside 13 analysts	$0.50 85.60% Downside	+86.7%	·
SNTI Senti Biosciences	Dec 15, 2023	HOLD	Strong Buy +2785.4% avg upside 7 analysts	—	+45.8%	·
KPTI Karyopharm Therapeutics	Dec 15, 2023	HOLD	Strong Buy +989.1% avg upside 18 analysts	—	-9.7%	·
LKFT Lakefront Biotherapeutics	Aug 22, 2023	HOLD	Buy +287.6% avg upside 24 analysts	$40.00 45.75% Upside	-35.0%	·
IOVA Iovance Biotherapeutics	May 22, 2023	BUY	Strong Buy +59.2% avg upside 25 analysts	$23.00 172.83% Upside	+29.3%	·
TSHA Taysha Gene Therapies	Jan 27, 2023	HOLD	Strong Buy +170.0% avg upside 21 analysts	$3.00 43.74% Downside	-15.9%	·
TECX Tectonic Therapeutic	Jan 05, 2022	HOLD	Strong Buy +87.2% avg upside 24 analysts	$3.00 90.14% Downside	-62.0%	·
BMRN BioMarin Pharmaceutical	Mar 12, 2021	HOLD	Strong Buy +48.1% avg upside 52 analysts	—	-1.0%	·
IDYA IDEAYA Biosciences	Mar 12, 2021	HOLD	Strong Buy +25.1% avg upside 29 analysts	—	-44.2%	·
NGNE Neurogene	Mar 12, 2021	HOLD	Strong Buy +28.7% avg upside 23 analysts	—	-82.2%	·
RARE Ultragenyx Pharmaceutical	Mar 12, 2021	HOLD	Strong Buy +245.2% avg upside 36 analysts	—	-48.5%	·
CHRS Coherus Biosciences	Mar 12, 2021	HOLD	Buy +837.1% avg upside 18 analysts	—	-24.1%	·
ARGX Argenx Se	Mar 04, 2021	BUY	Strong Buy -16.9% avg upside 47 analysts	$340.00 66.16% Downside	-8.6%	·
ARCT Arcturus Therapeutics	Mar 01, 2021	HOLD	Buy +110.3% avg upside 36 analysts	$60.00 307.04% Upside	-59.6%	·
NRIX Nurix Therapeutics	Feb 16, 2021	BUY	Strong Buy +23.2% avg upside 28 analysts	—	-59.7%	·
CYPH Cypherpunk Technologies	Jan 29, 2021	BUY	Buy +268.8% avg upside 9 analysts	$5.00 103.99% Upside	-26.6%	·
SNDX Syndax Pharmaceuticals	Jan 29, 2021	BUY	Strong Buy +79.2% avg upside 27 analysts	$37.00 86.45% Upside	-22.2%	·
ORIC Oric Pharmaceuticals	Aug 12, 2020	BUY	Strong Buy +91.8% avg upside 19 analysts	$45.00 259.99% Upside	-25.1%	·
TARA Protara Therapeutics	Mar 28, 2019	HOLD	Strong Buy +1237.1% avg upside 21 analysts	$40.00 944.38% Upside	+9.3%	·
SRL Scully Royalty	Oct 03, 2017	BUY	Strong Buy 3 analysts	—	-34.1%	·
GILD Gilead Sciences	May 18, 2010	BUY	Strong Buy -18.6% avg upside 66 analysts	$27.50 81.06% Downside	+5.3%	·

🔒 38 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Michael Ulz — Frequently Asked Questions

How accurate are Michael Ulz's stock ratings?

Based on the calls 13Foresight could measure, about 45% of Michael's ratings were profitable over a one-year hold, with an average return of -3.4% per rating, or -123.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Michael ranked on 13Foresight?

Michael Ulz is currently ranked #1947 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Michael cover?

Michael most recently has ratings on DYN, IONS, GUTS, ARWR, RYTM, CABA, RCKT, AARD, KYTX, SLN, BIOA, ZNTL and 31 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Michael Ulz

Rating Distribution

Welcome to 13Foresight!